Mirum Pharmaceuticals Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: Mirum Pharmaceuticals Inc.
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: Foster City
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: MIRM
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0001759425
EIN: 83-1281555
Wikidata ID: Q113503532

Board of directors

Follow this board

Christopher Peetz · Director · CHIEF EXECUTIVE OFFICER
Since 2023
Laura Brege · Director
Since 2023
Laurent Fischer · Director
Since 2023
Lon Cardon · Director
Since 2023
Michael G. Grey · Director
Since 2023
Patrick J. Heron · Director
Since 2023
Saira Ramasastry · Director
Since 2023
Timothy P. Walbert · Director Overboarded
Since 2023
William Fairey · Director
Since 2023

Chief executives

Christopher Peetz · President and CEO

Dates unknown

Director election results

Annual meeting of June 15, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Timothy P. Walbert

69.7%
William Fairey

86.8%

Board connections

8 of this board's directors also sit on 18 other boards. 18 are in the same sector.

Shared director Other board Same sector +2 more in the list below

Arcutis Biotherapeutics Inc. Same sector
via Christopher Peetz and Patrick J. Heron
ACADIA Pharmaceuticals Inc. Same sector
via Laura Brege
Ascendis Pharma A/S Same sector
via William Fairey
BioMarin Pharmaceutical Inc. Same sector
via Timothy P. Walbert
Century Therapeutics Inc. Same sector
via Timothy P. Walbert
Edgewise Therapeutics Inc. Same sector
via Laura Brege
Faeth Therapeutics Inc. Same sector
via Saira Ramasastry
Kardigan Inc. Same sector
via Timothy P. Walbert
Latigo Biotherapeutics Inc. Same sector
via Timothy P. Walbert
Lycia Therapeutics Inc. Same sector
via Laurent Fischer
MBX Biosciences Inc. Same sector
via Patrick J. Heron
Odyssey Therapeutics Inc. Same sector
via Timothy P. Walbert
OnKure Therapeutics Inc. Same sector
via Michael G. Grey
Pacira BioSciences Inc. Same sector
via Laura Brege
Rein Therapeutics Inc. Same sector
via William Fairey
Sagimet Biosciences Inc. Same sector
via Timothy P. Walbert
Spruce Biosciences Inc. Same sector
via Michael G. Grey
Vir Biotechnology Inc. Same sector
via Saira Ramasastry

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $8,999,984; 1 purchase by 1 insider
Sold, last 12 months: $44,001,968; 60 sales by 7 insiders

Date	Insider	Transaction	Shares	Price	Value
Nov 4, 2026	Christopher Peetz Director, Officer (CHIEF EXECUTIVE OFFICER)	Option exercise	+20,000	$2.94	$58,720
Nov 4, 2026	Christopher Peetz Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−20,000	$90.00	$1,800,000
Oct 16, 2026	Howe Jolanda Officer (SVP, GLOBAL CONTROLLER)	Option exercise	+16,112	$19.24	$309,995
Oct 6, 2026	Christopher Peetz Director, Officer (CHIEF EXECUTIVE OFFICER)	Option exercise	+5,305	$19.19	$101,803
Oct 6, 2026	Christopher Peetz Director, Officer (CHIEF EXECUTIVE OFFICER)	Option exercise	+6,892	$15.87	$109,376
Sep 14, 2026	Eric Bjerkholt Officer (CHIEF FINANCIAL OFFICER)	Open-market sale	−9,943	$98.37	$978,093
Sep 11, 2026	Eric Bjerkholt Officer (CHIEF FINANCIAL OFFICER)	Option exercise	+18,333	—	—
Sep 2, 2026	Howe Jolanda Officer (SVP, GLOBAL CONTROLLER)	Open-market sale	−658	$100.00	$65,800
Sep 1, 2026	Christopher Peetz Director, Officer (CHIEF EXECUTIVE OFFICER)	Option exercise	+30,000	$2.94	$88,200
Sep 1, 2026	Christopher Peetz Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−8,312	$98.08	$815,241
Sep 1, 2026	Christopher Peetz Director, Officer (CHIEF EXECUTIVE OFFICER)	Open-market sale	−21,688	$98.91	$2,145,160
Aug 18, 2026	Howe Jolanda Officer (SVP, GLOBAL CONTROLLER)	Option exercise	+40,000	$6.27	$250,800
Aug 18, 2026	Howe Jolanda Officer (SVP, GLOBAL CONTROLLER)	Open-market sale	−40,000	$100.00	$4,000,000
Aug 11, 2026	Eric Bjerkholt Officer (CHIEF FINANCIAL OFFICER)	Open-market sale	−6,001	$99.90	$599,500
Aug 10, 2026	Christopher Peetz Director, Officer (CHIEF EXECUTIVE OFFICER)	Option exercise	+20,000	$2.94	$58,800

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about Mirum Pharmaceuticals Inc.

Who is the CEO of Mirum Pharmaceuticals Inc.?

Christopher Peetz is Mirum Pharmaceuticals Inc.'s President and CEO.

How many directors are on Mirum Pharmaceuticals Inc.'s board?

Mirum Pharmaceuticals Inc.'s board has 9 directors: Christopher Peetz, Laura Brege, Laurent Fischer, Lon Cardon, Michael G. Grey, Patrick J. Heron, Saira Ramasastry, Timothy P. Walbert and William Fairey.

Are Mirum Pharmaceuticals Inc. insiders buying or selling shares?

Over the last 12 months, Mirum Pharmaceuticals Inc. insiders bought $9.0 million of shares in 1 purchase and sold $44.0 million of shares in 60 sales on the open market, as reported to the SEC on Forms 4 and 5.

How is Mirum Pharmaceuticals Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="mirum-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.